-+ 0.00%
-+ 0.00%
-+ 0.00%

Corcept Reports Positive Phase 2 Results for Lifyorli Combination in Platinum-Resistant Ovarian Cancer

PUBT·10/26/2026 12:05:30
Listen to the news
Corcept Reports Positive Phase 2 Results for Lifyorli Combination in Platinum-Resistant Ovarian Cancer
  • Corcept Therapeutics reported positive results from Part A of its 95-patient Phase 2 BELLA trial in platinum-resistant ovarian cancer.
  • Lifyorli combined with nab-paclitaxel and bevacizumab showed clinically meaningful tumor responses, delayed disease progression and survival outcomes.
  • Results were more pronounced in patients who had not previously received bevacizumab.
  • No new safety signals emerged; Lifyorli is not approved for use with bevacizumab.
  • Complete BELLA Part A results will be presented at a medical conference next year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202610260800BIZWIRE_USPR_____20261026_BW868995) on October 26, 2026, and is solely responsible for the information contained therein.